WO1996012520A1 - Electroporetic gene and drug therapy by induced electric fields - Google Patents
Electroporetic gene and drug therapy by induced electric fields Download PDFInfo
- Publication number
- WO1996012520A1 WO1996012520A1 PCT/US1995/008138 US9508138W WO9612520A1 WO 1996012520 A1 WO1996012520 A1 WO 1996012520A1 US 9508138 W US9508138 W US 9508138W WO 9612520 A1 WO9612520 A1 WO 9612520A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- preselected
- molecules
- blood vessel
- patient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/20—Applying electric currents by contact electrodes continuous direct currents
- A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
- A61N1/303—Constructional details
- A61N1/306—Arrangements where at least part of the apparatus is introduced into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
Definitions
- the present invention relates to the treatment of ailments in humans and other mammals, and more particularly, to an apparatus and method for in vivo delivering of pharmaceutical compounds and genes into live cells of a patient.
- retroviruses as the carrier of the gene into the cells.
- a retrovirus enters a target cell, it integrates essentially randomly in the genome and thus has the potential for introducing mutational damage by the mere fact of its insertion. If the virus integrates adjacent to an oncogeny, malignant transformation of the target cell can result.
- Electroporation is a convenient purely physical method for introducing drugs and genes into living cells. It is known that genes and other molecules such as pharmaceutical compounds can be incorporated into live cells through a process known as electroporation. In the typical experiment, the genes or other molecules are mixed with the live cells in a buffer medium in a chamber with two electrodes. A voltage pulse is applied between the electrodes to create the electric field. The cell membranes are transiently made porous and the genes or molecules enter the cells. There they can modify the genome of the cell. Examples of the prior art are: U.S. patent 4,970,154 of Chang, U.S. patent 5,098,843 of Calvin and U.S. patent 5,128,257 of Baer. This direct contact method is not easily adapted to a live body situation which would require the implantation of the electrodes.
- Recent methods of gene therapy have used the procedure wherein a substantial amount (e.g. 10%) of a patient's blood is withdrawn and the red and white blood cells are separated over a lengthy time period (e.g. four hours). The red blood cells are then re-infused. A new gene is inserted into the separated white blood cells utilizing a retrovirus. The growth of the white cells is then stimulated before they are re-infused into the patient. The procedure must be repeated every few months and the costs can reach $100,000.00 annually. It would be desirable to eliminate the need for separating the white cells from the red blood cells. This in turn would eliminate the need to withdraw and re-infuse a portion of the patient's blood.
- an apparatus and method have not been provided to permit electroporation mediated, ex vivo, intra cellular drug and gene delivery through the blood vessels of a living patient. It would be desirable to provide such an apparatus and method because it would permit gene therapy of living patients by genetically modifying their lymphocytes. Such an apparatus and method would also be beneficial in providing a means for delivering drugs to selected tissues and organs of a living human body by encapsulating them into red blood cells. In general, such an apparatus and method would be advantageous in providing a means of delivery of antibodies, proteins, or other molecules into the red or white blood cells of a living patient.
- a coil is applied to the body of the patient for generating an electric field at a preselected location within a selected area or portion of tissue, preselected molecules are infused into the selected tissue, simultaneously an electric signal is applied to the applied coil to repeatedly subject the tissue to electric fields of a predetermined amplitude and duration.
- the parameters of the electric fields are precisely controlled in order to make the walls of preselected cells in the tissue transiently permeable to permit the molecules to enter said preselected cells without killing said cells.
- the device can include either one or more induction coils placed over the tissue, or alternatively, an induction coil that surrounds a limb or portion of the body containing the tissue.
- the electric signal is supplied to a power pack and the preselected molecules are infused with a supply pump.
- FIG. 1 illustrates a patient with a device applied to his body for effecting in vivo electroporation of molecules into a selected area or portion of the patient's body in accordance with the present invention.
- Fig. 2 is an enlarged perspective view of an alternative embodiment of the apparatus for effecting in vivo electroporation of molecules into a blood vessel.
- Fig. 2a is a section view taken on line 2a-2a of Fig. 2.
- Fig. 3 is a perspective view of another embodiment of the apparatus for effecting in vivo electroporation of molecules into a blood vessel.
- Fig. 4 is a perspective view of a further embodiment of the apparatus for effecting in vivo electroporation of molecules into a plurality of blood vessels.
- an embodiment of my apparatus as disclosed in the parent application includes a device 12 which is implanted in a patient 10 for repeatedly generating electric fields of a predetermined amplitude and duration.
- This device embodies an induction coil and takes advantage of Faraday's law of electromagnetic induction to generate electric fields by induction. It is well known that the movement of a conductor through a magnetic field can induce an electric current in the conductor.
- a time varying electric current through a coil can generate a changing or time varying magnetic field which can also induce an electric field in the adjacent space, which in the present case in the underlying tissue and blood vessels.
- the induced electric field can be controlled by selecting the appropriate primary coil and its driving current.
- the fields are generated by applying a predetermined electric signal or current to the coil of the device.
- T any closed curve and S is any surface bounded by it.
- T is a mathematical curve fixed in space, and 5 is a fixed surface. Then the time derivative can be taken outside the integral and we have
- the integral on the left is the emf, and that on the right is the negative rate of change of the flux linked by the circuit.
- the E- ield can exist in free space, and its line integral around any imaginary line fixed in space is the rate of change of the flux of B through that line. (Note that this is quite unlike the E- field produced by static charges, for in that case the line integral of E around a closed loop is always zero.)
- the parameters of the signal are selected so that a quantity of blood flowing within the selected blood vessel is subjected to short pulses of high intensity electric fields.
- Typical electric field amplitudes required are several kV/cm at frequencies between 50 and 500 kH j for a duration of a few hundred microseconds or milliseconds.
- FIG. 2 An exemplary embodiment of an implantable electric field generating device is illustrated in Figure 2.
- the electric field inside the blood vessel 14 is generated by an induction coil surrounding the blood vessel.
- a flexible single turn serpentine coil 16 surrounds the blood vessel 14.
- This coil is in the form of a serpentine coil 16 wound along a split dielectric cylinder 18 and having conductors 20 and 22 connected to a power pack 24.
- the device includes a fitting 26 for connection of a supply line or tube 28 from a supply pump 30.
- the supply line 28 may be provided with a spike tip as shown in Fig. 2a for communicating through the blood vessel.
- the dielectric cylinder can be expanded to be fit around the blood vessel 14. It may also be modified to extend around other external as well as internal parts of the body.
- the function of the signal generator in the power pack 24 ( Figure 2) is to generate a predetermined repetitive electric current signal which, when applied to the coil 16 results in applying short bursts of oscillating electric fields of a predetermined amplitude and duration to the blood flowing through the blood vessel 14.
- these fields are applied repeatedly and their amplitude and duration are sufficient to make the walls of preselected cells in the blood sufficiently permeable to permit the molecules to enter the preselected cells without killing them.
- an alternate embodiment is illustrated wherein an external pancake induction coil 32 is applied directly to an arm 34 of a patient.
- the coil is positioned directly over a blood vessel (not shown) and connected by conductors 36 and 38 to a pulse power module 40 which provides repetitive current signals to the coil.
- the current to the coils is time varying and induces electric fields in the blood vessels.
- the power module is controlled by means of a computer 42 connected thereto by cable 44.
- the computer controls the repetitive rate of the power supply to be commensurate to the blood flow rate in the vessel.
- the coil may be secured in place by a strap or tape 46. Drugs or genes are infused via a tube 48 and needle 50 into the vein upstream of the coil so that is passes with the blood through the electric field.
- This version can also be used for electroporation of other tissue of the body.
- the coil is placed closely adjacent the tissue to be electroporated and the appropriate electrical signal applied to achieve the desired electric field to produce electroporation of the tissue or cells of the tissue.
- the molecules to be introduced into the cells may be infused into the tissue by direct injection or by combinations of electroporation, iontophoresis and other means. This is particularly adaptable to the electroporation of tumors and the like. This approach eliminates the need for electrodes and possible conductivity problems sometimes associated with them.
- a further external embodiment is illustrated wherein like components are identified by the same reference numerals, a plurality of ring shaped induction coils 52, 54, 56, 58 and 60 are applied directly to the fingers of a patient.
- the coils are positioned on and encircle the fingers and are directly over a blood vessel (not shown) carrying blood to the ends of the fingers.
- the coils are connected by conductors 62, 64, 66, 68 and 70 to pulse power module 40 which provides repetitive current signals to the coil.
- the power module is controlled by means of a computer 42 connected thereto by a cable 44.
- the coil may be secured in place by a strap or tape 46.
- Drugs or genes are infused via a tube 48 and needle 50 into a vein upstream of the coils so that they flow through the electric field.
- Alternative arrangements of this encircling embodiment may also be applied to a single finger or to other limbs or portions of the body. It may also be used to electroporate other tissue or cells of the body, both internally and externally.
- This induction coil approach provides a convenient means of electroporation of cells of internal organs without the need for physical invasion of the body.
- the preferred waveform of the electrical signal provided by the signal generator in the power pack 40 is a bipolar oscillating pulse train.
- the induced electric field strength can be from 0.2kV/cm to 20kV/cm.
- the pulse length can be from one microsecond to one hundred microseconds.
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Electrotherapy Devices (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Saccharide Compounds (AREA)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69502733T DE69502733T2 (de) | 1994-10-25 | 1995-06-27 | Elektrophoretische gen- und medikamenttherapie mittels eines induzierten elektrischen feldes |
EP95925349A EP0788392B1 (en) | 1994-10-25 | 1995-06-27 | Electroporetic gene and drug therapy by induced electric fields |
DK95925349T DK0788392T3 (da) | 1994-10-25 | 1995-06-27 | Elektroforetisk gen- og medicinterapi ved hjælp af inducerede elektriske felter |
AU29515/95A AU2951595A (en) | 1994-10-25 | 1995-06-27 | Electroporetic gene and drug therapy by induced electric fields |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/328,895 US6132419A (en) | 1992-05-22 | 1994-10-25 | Electroporetic gene and drug therapy |
US08/328,895 | 1994-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996012520A1 true WO1996012520A1 (en) | 1996-05-02 |
Family
ID=23282925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/008138 WO1996012520A1 (en) | 1994-10-25 | 1995-06-27 | Electroporetic gene and drug therapy by induced electric fields |
Country Status (8)
Country | Link |
---|---|
US (1) | US6132419A (da) |
EP (1) | EP0788392B1 (da) |
AT (1) | ATE166585T1 (da) |
AU (1) | AU2951595A (da) |
DE (1) | DE69502733T2 (da) |
DK (1) | DK0788392T3 (da) |
ES (1) | ES2117871T3 (da) |
WO (1) | WO1996012520A1 (da) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003038112A2 (en) | 2001-10-26 | 2003-05-08 | Baylor College Of Medicine | A composition and method to alter lean body mass and bone properties in a subject |
US7361642B2 (en) | 2003-08-04 | 2008-04-22 | Vgx Pharmaceuticals, Inc. | Canine specific growth hormone releasing hormone |
US7517863B2 (en) | 2004-01-20 | 2009-04-14 | Vgx Pharmaceuticals, Inc. | Enhanced secretion/retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide |
WO2010137021A2 (en) | 2009-05-27 | 2010-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
US8058253B2 (en) | 2006-07-06 | 2011-11-15 | Vgx Pharmaceuticals, Inc. | Growth hormone releasing hormone treatment to decrease cholesterol levels |
US8188056B2 (en) | 2003-12-31 | 2012-05-29 | Vgx Pharmaceuticals, Inc. | Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation |
Families Citing this family (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6585763B1 (en) * | 1997-10-14 | 2003-07-01 | Vascusense, Inc. | Implantable therapeutic device and method |
US6775574B1 (en) * | 1997-11-07 | 2004-08-10 | Medtronic, Inc. | Method and system for myocardial infarction repair |
CA2320377C (en) | 1998-02-24 | 2008-07-08 | Boston Scientific Limited | High flow rate dialysis catheters and related methods |
AU3973599A (en) | 1998-05-08 | 1999-11-29 | Genetronics, Inc. | Electrically induced vessel vasodilation |
US6300108B1 (en) * | 1999-07-21 | 2001-10-09 | The Regents Of The University Of California | Controlled electroporation and mass transfer across cell membranes |
US20060127466A1 (en) * | 2000-02-25 | 2006-06-15 | Arindam Sen | Method for transdermal or intradermal delivery of molecules |
BR0108959A (pt) * | 2000-03-03 | 2003-10-14 | Valentis Inc | Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico |
US6892099B2 (en) | 2001-02-08 | 2005-05-10 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits, virtual face lift and body sculpturing by electroporation |
US8251986B2 (en) | 2000-08-17 | 2012-08-28 | Angiodynamics, Inc. | Method of destroying tissue cells by eletroporation |
US6697670B2 (en) | 2001-08-17 | 2004-02-24 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation with improved comfort of patients |
US6795728B2 (en) | 2001-08-17 | 2004-09-21 | Minnesota Medical Physics, Llc | Apparatus and method for reducing subcutaneous fat deposits by electroporation |
US6994706B2 (en) * | 2001-08-13 | 2006-02-07 | Minnesota Medical Physics, Llc | Apparatus and method for treatment of benign prostatic hyperplasia |
USRE42016E1 (en) | 2001-08-13 | 2010-12-28 | Angiodynamics, Inc. | Apparatus and method for the treatment of benign prostatic hyperplasia |
US6733518B2 (en) | 2001-10-31 | 2004-05-11 | Seacoast Technologies, Inc. | Method and apparatus for thermal therapy |
US7211083B2 (en) * | 2003-03-17 | 2007-05-01 | Minnesota Medical Physics, Llc | Apparatus and method for hair removal by electroporation |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
EP2474281B1 (en) | 2003-12-24 | 2019-03-27 | The Regents of The University of California | Tissue ablation with irreversible electroporation |
US8298222B2 (en) | 2003-12-24 | 2012-10-30 | The Regents Of The University Of California | Electroporation to deliver chemotherapeutics and enhance tumor regression |
US7840263B2 (en) | 2004-02-27 | 2010-11-23 | Cardiac Pacemakers, Inc. | Method and apparatus for device controlled gene expression |
US7764995B2 (en) | 2004-06-07 | 2010-07-27 | Cardiac Pacemakers, Inc. | Method and apparatus to modulate cellular regeneration post myocardial infarct |
US7729761B2 (en) | 2004-07-14 | 2010-06-01 | Cardiac Pacemakers, Inc. | Method and apparatus for controlled gene or protein delivery |
SG123643A1 (en) * | 2004-12-28 | 2006-07-26 | Nanyan Polytechnic | Programmable apparatus and method for optimizing and real time monitoring of gene transfection basedon user configured arbitrary waveform pulsing tra in |
EP2816118B1 (en) | 2005-05-31 | 2018-10-17 | The Regents of the University of Colorado, a body corporate | Methods for delivering genes |
US8114070B2 (en) | 2005-06-24 | 2012-02-14 | Angiodynamics, Inc. | Methods and systems for treating BPH using electroporation |
US20060293730A1 (en) | 2005-06-24 | 2006-12-28 | Boris Rubinsky | Methods and systems for treating restenosis sites using electroporation |
JP2009529930A (ja) * | 2006-03-13 | 2009-08-27 | ノボ・ノルデイスク・エー/エス | 二目的通信手段を備えた医療システム |
WO2007104755A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Secure pairing of electronic devices using dual means of communication |
WO2008048620A2 (en) | 2006-10-16 | 2008-04-24 | The Regents Of The University Of California | Gels with predetermined conductivity used in irreversible electroporation of tissue |
WO2009121009A2 (en) | 2008-03-27 | 2009-10-01 | The Regents Of The University Of California | Irreversible electroporation device for use in attenuating neointimal |
US8926606B2 (en) | 2009-04-09 | 2015-01-06 | Virginia Tech Intellectual Properties, Inc. | Integration of very short electric pulses for minimally to noninvasive electroporation |
US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
US9598691B2 (en) | 2008-04-29 | 2017-03-21 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
WO2009137800A2 (en) | 2008-05-09 | 2009-11-12 | Angiodynamics, Inc. | Electroporation device and method |
US8849395B2 (en) | 2008-05-30 | 2014-09-30 | Boston Scientific Scimed, Inc. | Guide catheter having vasomodulating electrodes |
US9173704B2 (en) | 2008-06-20 | 2015-11-03 | Angiodynamics, Inc. | Device and method for the ablation of fibrin sheath formation on a venous catheter |
WO2010008834A2 (en) | 2008-06-23 | 2010-01-21 | Angiodynamics, Inc. | Treatment devices and methods |
WO2010085765A2 (en) | 2009-01-23 | 2010-07-29 | Moshe Meir H | Therapeutic energy delivery device with rotational mechanism |
US8231603B2 (en) | 2009-02-10 | 2012-07-31 | Angiodynamics, Inc. | Irreversible electroporation and tissue regeneration |
US20100249488A1 (en) * | 2009-03-30 | 2010-09-30 | MagneGene, Inc. | Method of contactless magnetic electroporation |
US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
USD630321S1 (en) | 2009-05-08 | 2011-01-04 | Angio Dynamics, Inc. | Probe handle |
US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
US20110118732A1 (en) | 2009-11-19 | 2011-05-19 | The Regents Of The University Of California | Controlled irreversible electroporation |
RU2539991C2 (ru) | 2009-12-16 | 2015-01-27 | Кронтек Фарма Аб | Впрыскивающие игла и устройство |
EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
HRP20220796T1 (hr) | 2010-10-01 | 2022-10-14 | ModernaTX, Inc. | Ribonukleinske kiseline koje sadrže n1-metil-pseudouracil i njihove uporabe |
WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
EP2670426B1 (en) | 2011-01-31 | 2017-05-10 | The General Hospital Corporation | Multimodal trail molecules and uses in cellular therapies |
CA2831613A1 (en) | 2011-03-31 | 2012-10-04 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
CN103717249B (zh) | 2011-06-15 | 2017-03-22 | 克洛恩泰克制药股份公司 | 注射针和装置 |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
RS63244B1 (sr) | 2011-12-16 | 2022-06-30 | Modernatx Inc | Kompozicije modifikovane mrna |
DE102012000354A1 (de) * | 2012-01-11 | 2013-07-11 | Udo Tartler | Vorrichtung für eine Angussöffnung einer Gussform |
US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
WO2013151664A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
US9605074B2 (en) | 2012-08-30 | 2017-03-28 | The General Hospital Corporation | Multifunctional nanobodies for treating cancer |
WO2014064534A2 (en) | 2012-10-05 | 2014-05-01 | Chrontech Pharma Ab | Injection needle, device, immunogenic compositions and method of use |
PL2922554T3 (pl) | 2012-11-26 | 2022-06-20 | Modernatx, Inc. | Na zmodyfikowany na końcach |
US9888956B2 (en) | 2013-01-22 | 2018-02-13 | Angiodynamics, Inc. | Integrated pump and generator device and method of use |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014145042A1 (en) | 2013-03-15 | 2014-09-18 | Loma Linda University | Treatment of autoimmune diseases |
CA2913155A1 (en) | 2013-05-21 | 2014-11-27 | President And Fellows Of Harvard College | Engineered heme-binding compositions and uses thereof |
SG11201602503TA (en) | 2013-10-03 | 2016-04-28 | Moderna Therapeutics Inc | Polynucleotides encoding low density lipoprotein receptor |
US10166321B2 (en) | 2014-01-09 | 2019-01-01 | Angiodynamics, Inc. | High-flow port and infusion needle systems |
CN112807074A (zh) | 2014-05-12 | 2021-05-18 | 弗吉尼亚暨州立大学知识产权公司 | 电穿孔系统 |
US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
WO2016168601A1 (en) | 2015-04-17 | 2016-10-20 | Khalid Shah | Agents, systems and methods for treating cancer |
US10660691B2 (en) | 2015-10-07 | 2020-05-26 | Angiodynamics, Inc. | Multiple use subassembly with integrated fluid delivery system for use with single or dual-lumen peristaltic tubing |
US10233419B2 (en) | 2016-06-30 | 2019-03-19 | Zymergen Inc. | Apparatuses and methods for electroporation |
EP3559228A4 (en) * | 2016-11-09 | 2021-01-27 | Sigma Genetics, Inc. | SYSTEMS, DEVICES AND METHODS FOR ELECTROPORATION INDUCED BY MAGNETIC FIELDS |
US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
US20230330211A1 (en) | 2020-03-27 | 2023-10-19 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronaviruses |
US20230295244A1 (en) | 2021-09-29 | 2023-09-21 | Svenska Vaccinfabriken Produktion Ab | Compositions and methods for treating and preventing coronaviruses |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2132486A (en) * | 1982-12-23 | 1984-07-11 | Electro Biology Inc | Applicator head for electromagnetic treatment of an afflicted body region |
US4818697A (en) * | 1986-10-27 | 1989-04-04 | Life Resonances, Inc. | Techniques for enhancing the permeability of ions through membranes |
US4970154A (en) * | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
US5304120A (en) * | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2320462A (en) * | 1940-09-27 | 1943-06-01 | Nawells Frank | Clock operated switch |
US3978864A (en) * | 1965-10-11 | 1976-09-07 | L. B. Smith Estates, Inc. | Electrotherapeutic treatment head |
US4374669A (en) * | 1975-05-09 | 1983-02-22 | Mac Gregor David C | Cardiovascular prosthetic devices and implants with porous systems |
SU624640A1 (ru) * | 1977-03-28 | 1978-09-25 | Каунасский Медицинский Институт | Способ электрофореза |
DE3166638D1 (en) * | 1980-12-23 | 1984-11-15 | Kontron Ag | Implantable electrode |
US4639244A (en) * | 1983-05-03 | 1987-01-27 | Nabil I. Rizk | Implantable electrophoretic pump for ionic drugs and associated methods |
US4842598A (en) * | 1984-12-06 | 1989-06-27 | Controlled Release Technologies, Inc. | Therapeutic agent delivery system and method |
US4690130A (en) * | 1985-12-19 | 1987-09-01 | Mirell Stuart G | Electromagnetic therapy control system |
US4906576A (en) * | 1986-05-09 | 1990-03-06 | Electropore, Inc. | High speed, high power apparatus for vesicle prealignment, poration, loading and fusion in uniform electric fields and method therefor |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
US4801459A (en) * | 1986-08-05 | 1989-01-31 | Liburdy Robert P | Technique for drug and chemical delivery |
US5290409A (en) * | 1986-10-27 | 1994-03-01 | Life Resonances, Inc. | Methods and apparatus for regulating transmembrane ion movement utilizing selective harmonic frequencies and simultaneous multiple ion regulation |
US5098843A (en) * | 1987-06-04 | 1992-03-24 | Calvin Noel M | Apparatus for the high efficiency transformation of living cells |
US5128257A (en) * | 1987-08-31 | 1992-07-07 | Baer Bradford W | Electroporation apparatus and process |
JP2798459B2 (ja) * | 1988-01-21 | 1998-09-17 | マサチユセツツ・インスチチユート・オブ・テクノロジー | エレクトロポレーションを利用した診断装置及び分子の組織内移動装置 |
US5389069A (en) * | 1988-01-21 | 1995-02-14 | Massachusetts Institute Of Technology | Method and apparatus for in vivo electroporation of remote cells and tissue |
WO1989010690A1 (en) * | 1988-05-02 | 1989-11-16 | University Of South Florida | Method for electrofusing biological particles to tissues |
US5224922A (en) * | 1988-05-19 | 1993-07-06 | Kurtz Warren H | Quasistatic biological cell and tissue modifier |
US5183456A (en) * | 1989-11-15 | 1993-02-02 | Life Resonances, Inc. | Method and apparatus for the treatment of cancer |
US5016615A (en) * | 1990-02-20 | 1991-05-21 | Riverside Research Institute | Local application of medication with ultrasound |
US5236413B1 (en) * | 1990-05-07 | 1996-06-18 | Andrew J Feiring | Method and apparatus for inducing the permeation of medication into internal tissue |
ATE123658T1 (de) * | 1990-06-15 | 1995-06-15 | Cortrak Medical Inc | Vorrichtung zur abgabe von medikamenten. |
US5087243A (en) * | 1990-06-18 | 1992-02-11 | Boaz Avitall | Myocardial iontophoresis |
US5246437A (en) * | 1992-04-10 | 1993-09-21 | Abela George S | Cell treatment apparatus and method |
US5501662A (en) * | 1992-05-22 | 1996-03-26 | Genetronics, Inc. | Implantable electroporation method and apparatus for drug and gene delivery |
US5318514A (en) * | 1992-08-17 | 1994-06-07 | Btx, Inc. | Applicator for the electroporation of drugs and genes into surface cells |
US5439440A (en) * | 1993-04-01 | 1995-08-08 | Genetronics, Inc. | Electroporation system with voltage control feedback for clinical applications |
US5419763B1 (en) * | 1994-01-04 | 1997-07-15 | Cor Trak Medical Inc | Prostatic drug-delivery catheter |
-
1994
- 1994-10-25 US US08/328,895 patent/US6132419A/en not_active Expired - Fee Related
-
1995
- 1995-06-27 DK DK95925349T patent/DK0788392T3/da active
- 1995-06-27 EP EP95925349A patent/EP0788392B1/en not_active Expired - Lifetime
- 1995-06-27 ES ES95925349T patent/ES2117871T3/es not_active Expired - Lifetime
- 1995-06-27 AU AU29515/95A patent/AU2951595A/en not_active Abandoned
- 1995-06-27 WO PCT/US1995/008138 patent/WO1996012520A1/en active IP Right Grant
- 1995-06-27 AT AT95925349T patent/ATE166585T1/de not_active IP Right Cessation
- 1995-06-27 DE DE69502733T patent/DE69502733T2/de not_active Expired - Lifetime
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2132486A (en) * | 1982-12-23 | 1984-07-11 | Electro Biology Inc | Applicator head for electromagnetic treatment of an afflicted body region |
US4818697A (en) * | 1986-10-27 | 1989-04-04 | Life Resonances, Inc. | Techniques for enhancing the permeability of ions through membranes |
US4970154A (en) * | 1987-10-09 | 1990-11-13 | Baylor College Of Medicine | Method for inserting foreign genes into cells using pulsed radiofrequency |
US5304120A (en) * | 1992-07-01 | 1994-04-19 | Btx Inc. | Electroporation method and apparatus for insertion of drugs and genes into endothelial cells |
US5273525A (en) * | 1992-08-13 | 1993-12-28 | Btx Inc. | Injection and electroporation apparatus for drug and gene delivery |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003038112A2 (en) | 2001-10-26 | 2003-05-08 | Baylor College Of Medicine | A composition and method to alter lean body mass and bone properties in a subject |
US7361642B2 (en) | 2003-08-04 | 2008-04-22 | Vgx Pharmaceuticals, Inc. | Canine specific growth hormone releasing hormone |
US8188056B2 (en) | 2003-12-31 | 2012-05-29 | Vgx Pharmaceuticals, Inc. | Reducing arthritis and lameness in subjects by growth hormone releasing hormone (GHRH) supplementation |
US7517863B2 (en) | 2004-01-20 | 2009-04-14 | Vgx Pharmaceuticals, Inc. | Enhanced secretion/retention of growth hormone releasing hormone (GHRH) from muscle cells by species-specific signal peptide |
US8058253B2 (en) | 2006-07-06 | 2011-11-15 | Vgx Pharmaceuticals, Inc. | Growth hormone releasing hormone treatment to decrease cholesterol levels |
WO2010137021A2 (en) | 2009-05-27 | 2010-12-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of generating connective tissue |
Also Published As
Publication number | Publication date |
---|---|
DK0788392T3 (da) | 1999-03-01 |
ATE166585T1 (de) | 1998-06-15 |
US6132419A (en) | 2000-10-17 |
ES2117871T3 (es) | 1998-08-16 |
DE69502733T2 (de) | 1998-09-24 |
EP0788392B1 (en) | 1998-05-27 |
EP0788392A1 (en) | 1997-08-13 |
AU2951595A (en) | 1996-05-15 |
DE69502733D1 (de) | 1998-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6132419A (en) | Electroporetic gene and drug therapy | |
US5501662A (en) | Implantable electroporation method and apparatus for drug and gene delivery | |
US5921244A (en) | Internal magnetic device to enhance drug therapy | |
CA2218255C (en) | Method of treatment using electroporation-mediated delivery of drugs and genes | |
US5869326A (en) | Electroporation employing user-configured pulsing scheme | |
US6733485B1 (en) | Microstimulator-based electrochemotherapy methods and systems | |
EP0378132A2 (en) | A device for the administration of medication by iontopheresis for local - regional treatment. | |
EP1515775A2 (en) | Method and device for treating concer with electrical therapy in conjunction with chemotherapeutic agents and radiation therapy | |
US20040254618A1 (en) | Implantable device and method for the electrical treatment of cancer | |
US20220387812A1 (en) | Device for, and method of, neuromodulation with closed-loop micromagnetic hybrid waveforms to relieve pain | |
US11654292B2 (en) | Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients | |
US7493168B2 (en) | Electrical stimulation to treat hair loss | |
AU4177100A (en) | Method and apparatus for reducing electroporation-mediated muscle reaction and pain response | |
US6181962B1 (en) | Electrically activated substance and method for making the same | |
AU2022215308B2 (en) | Device for, and method of, neuromodulation with closed-loop micromagnetic hybrid waveforms to relieve pain | |
JPH02111378A (ja) | 電磁生体刺激装置 | |
Salford et al. | Treatment of rat glioma with electrochemotherapy | |
WO2003063950A2 (en) | Electrical stimulation to treat hair loss | |
Gehl | Electroporation for Drug and Gene Delivery | |
AU2003208964A1 (en) | Electrical stimulation to treat hair loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CN JP KR MX RU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995925349 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995925349 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995925349 Country of ref document: EP |